Rezolute Inc
RZLT
NASDAQ
Biotechnology
$4.60
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $442.94M
Volume 656.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-81.48M
TTM
-11.6%
YoY
Operating Cash Flow
$-73.48M
TTM
-12.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.7 | 5.0 | 6.7 | 9.9 | 6.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 20.0 | 25.9 | 19.8 | 24.2 | 17.4 |
Operating Income | -20.0 | -25.9 | -19.8 | -24.2 | -17.4 |
EBITDA | -20.0 | -25.8 | -19.8 | -24.2 | -17.4 |
Other Income / Expense | -0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 1.1 | 1.5 | 1.7 | 1.4 | 1.2 |
Income Before Income Taxes | -18.9 | -24.4 | -18.2 | -22.8 | -16.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -18.9 | -24.4 | -18.2 | -22.8 | -16.2 |
Consolidated Net Income / Loss | -18.9 | -24.4 | -18.2 | -22.8 | -16.2 |
Net Income Attributable to Common Shareholders | -18.9 | -24.4 | -18.2 | -22.8 | -16.2 |
Basic EPS | -$0.27 | -$0.26 | -$0.18 | -$0.22 | -$0.16 |
Diluted EPS | -$0.27 | -$0.26 | -$0.18 | -$0.22 | -$0.16 |
Basic Shares Outstanding | 70.0M | 94.3M | 103.4M | 103.7M | 104.0M |
Diluted Shares Outstanding | 70.0M | 94.3M | 103.4M | 103.7M | 104.0M |